Image Cytometry Analyzes CAR-T Cells for Solid Tumor Therapy

SLAS (Society for Laboratory Automation and Screening)

Oak Brook, IL – The April 2023 issue of SLAS Discovery contains six full-length articles and one mini-review covering high-throughput screening (HTS) for protease-inhibiting drugs, high-content phenotypic screening and other life sciences research.

Featured in this month's issue is the article "High-Throughput Method to Analyze the Cytotoxicity of CAR-T Cells in a 3D Tumor Spheroid Model Using Image Cytometry," by Zurowski, et al, where the authors focus on the use of chimeric antigen receptor T (CAR-T) cells targeting prostate-specific membrane antigen (PSMA), an antigen found in prostate cancer tumor cells. CAR-T cell therapy has proven to be a reliable treatment option for various hematological malignancies, and the discovery of an assay for testing this therapy to solid tumors could yield new possibilities in treating the tumor type present in 90% of all adult human cancers.

The researchers developed a high-throughput assay to analyze the effects of CAR-T cells on 3D tumor spheroid models using plate-based image cytometry. With this study, the authors demonstrate the potential benefits of using the proposed method for assessing multiple parameters such as potency, specificity and even location of the CAR-T cells in relation to the spheroids, which could improve the rate of identification for effective CAR-T cell therapies in the treatment of solid tumors.

Read this original research article to learn how image-based cytometry can overcome the limitations of conventional CAR-T characterization methods, along with more research articles in the April issue of SLAS Discovery.

The April issue of SLAS Discovery includes these additional articles:

Access to the April issue of SLAS Discovery is available at https://slas-discovery.org/issue/S2472-5552(23)X0004-5

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.